MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
New front launched in war on malaria
With $29.3M from the Gates Foundation, Rockville company opens plant today.
Fred Binka, Sanaria Advisory Board Member, featured in Newsweek
Read the full Newsweek article: “Giving Globally: The Search for Solutions“
Sanaria featured in National Geographic magazine
Read the full story: Bedlam in the Blood, Malaria (Membership required). NatGeo Article
Sanaria featured in ‘Kill or Cure’ documentary
Kill or Cure? The Malaria Vaccine takes viewers into the starkly different worlds of two cutting-edge investigators who may be moving us tantalizingly close to an achievement unheard of in the history of immunizations - an effective vaccine against a parasitic disease.
Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company, announced the receipt of two multi-year Small Business Innovation Research (SBIR) Grants from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The grants will enhance the development of its whole parasite Malaria Vaccine. The Phase II grant is to establish multiple strains of the parasite that can be used to assess the effectiveness of Sanaria's Malaria Vaccine.
Bush recognizes social entrepreneurship
Like many such events, the recent White House Summit on malaria, which featured a speech and new grant announcements by Melinda Gates, was carefully choreographed with few surprises. But there was one. President Bush began the closing keynote address by saying, “I want to thank those members of my Cabinet who are here, the ambassadors, the members of Congress, and I want to thank the social entrepreneurs who are with us today.” Bush then cited the Bill & Melinda Gates Foundation as “a fantastic example of social entrepreneurship, using business acumen to address social problems.” Read more in the original Seattle PI article, with its discussion of Sanaria’s approach to malaria vaccines and its business model.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.